PURPOSE: We present the preliminary results of intensity-modulated radiation therapy with helical tomotherapy (HT) for clinically localized prostate cancer. METHODS: Regularly followed 241 consecutive patients, who were treated with HT between June 2006 and December 2010, were included in this retrospective study. Most patients received both relatively long-term neoadjuvant and adjuvant androgen deprivation therapy (ADT). Patients received 78 Gy in the intermediate high-risk group and 74 Gy in the low-risk group. Biochemical disease-free survival (bDFS) followed the Phoenix definition. Toxicity was scored according to the Radiation Therapy Oncology Group morbidity grading scale. RESULTS: The median follow-up time from the start date of HT was 35 months. The rates of acute Grade 2 gastro-intestinal (GI) and genitor-urinary (GU) toxicities were 11.2 and 24.5 %. No patients experienced acute Grade 3 or higher symptoms. The rates of late Grade 2 and 3 GI toxicities were 6.6 and 0.8 %, and those of late Grade 2 and 3 GU toxicities were 8.3 % and 1.2 %. No patients experienced late Grade 4 toxicity. The 3-year bDFS rates for low, intermediate, and high-risk group patients were 100, 100, and 95.8 %, respectively. We observed clinical relapse in two high-risk patients, resulting in a 3-year clinical DFS of 99.4 %. CONCLUSIONS: This preliminary report confirms the feasibility of HT in a large number of patients. We observed that HT is associated with low rates of acute and late toxicities, and HT in combination with relatively long-term ADT results in excellent short-term bDFS.
PURPOSE: We present the preliminary results of intensity-modulated radiation therapy with helical tomotherapy (HT) for clinically localized prostate cancer. METHODS: Regularly followed 241 consecutive patients, who were treated with HT between June 2006 and December 2010, were included in this retrospective study. Most patients received both relatively long-term neoadjuvant and adjuvant androgen deprivation therapy (ADT). Patients received 78 Gy in the intermediate high-risk group and 74 Gy in the low-risk group. Biochemical disease-free survival (bDFS) followed the Phoenix definition. Toxicity was scored according to the Radiation Therapy Oncology Group morbidity grading scale. RESULTS: The median follow-up time from the start date of HT was 35 months. The rates of acute Grade 2 gastro-intestinal (GI) and genitor-urinary (GU) toxicities were 11.2 and 24.5 %. No patients experienced acute Grade 3 or higher symptoms. The rates of late Grade 2 and 3 GI toxicities were 6.6 and 0.8 %, and those of late Grade 2 and 3 GU toxicities were 8.3 % and 1.2 %. No patients experienced late Grade 4 toxicity. The 3-year bDFS rates for low, intermediate, and high-risk group patients were 100, 100, and 95.8 %, respectively. We observed clinical relapse in two high-risk patients, resulting in a 3-year clinical DFS of 99.4 %. CONCLUSIONS: This preliminary report confirms the feasibility of HT in a large number of patients. We observed that HT is associated with low rates of acute and late toxicities, and HT in combination with relatively long-term ADT results in excellent short-term bDFS.
Authors: Navesh K Sharma; Tianyu Li; David Y Chen; Alan Pollack; Eric M Horwitz; Mark K Buyyounouski Journal: Int J Radiat Oncol Biol Phys Date: 2010-11-02 Impact factor: 7.038
Authors: Michael J Zelefsky; Zvi Fuks; Margie Hunt; Yoshiya Yamada; Christine Marion; C Clifton Ling; Howard Amols; E S Venkatraman; Steven A Leibel Journal: Int J Radiat Oncol Biol Phys Date: 2002-08-01 Impact factor: 7.038
Authors: William W Wong; Sujay A Vora; Steven E Schild; Gary A Ezzell; Paul E Andrews; Robert G Ferrigni; Scott K Swanson Journal: Cancer Date: 2009-12-01 Impact factor: 6.860
Authors: C V Sole; J L Lopez Guerra; R Matute; J Jaen; F Puebla; E Rivin; A Sanchez-Reyes; C Beltran; C Bourgier; F A Calvo; H Marsiglia Journal: Clin Transl Oncol Date: 2012-11-10 Impact factor: 3.405
Authors: Shea W Wilcox; Noel J Aherne; Linus C Benjamin; Bosco Wu; Thomaz de Campos Silva; Craig S McLachlan; Michael J McKay; Andrew J Last; Thomas P Shakespeare Journal: Onco Targets Ther Date: 2014-08-30 Impact factor: 4.147